After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug
Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.

Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.